T2 Biosystms Stock Fundamentals
TTOODelisted Stock | USD 0.18 0.05 21.74% |
T2 Biosystms fundamentals help investors to digest information that contributes to T2 Biosystms' financial success or failures. It also enables traders to predict the movement of TTOO Pink Sheet. The fundamental analysis module provides a way to measure T2 Biosystms' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to T2 Biosystms pink sheet.
TTOO |
T2 Biosystms Company Return On Equity Analysis
T2 Biosystms' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current T2 Biosystms Return On Equity | -6.22 |
Most of T2 Biosystms' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, T2 Biosystms is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
CompetitionBased on the latest financial disclosure, T2 Biosystms has a Return On Equity of -6.2214. This is 74.05% lower than that of the Biotechnology sector and 6.87% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
T2 Biosystms Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining T2 Biosystms's current stock value. Our valuation model uses many indicators to compare T2 Biosystms value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across T2 Biosystms competition to find correlations between indicators driving T2 Biosystms's intrinsic value. More Info.T2 Biosystms is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value T2 Biosystms by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for T2 Biosystms' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.TTOO Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses T2 Biosystms' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of T2 Biosystms could also be used in its relative valuation, which is a method of valuing T2 Biosystms by comparing valuation metrics of similar companies.T2 Biosystms is currently under evaluation in return on equity category among its peers.
TTOO Fundamentals
Return On Equity | -6.22 | ||||
Return On Asset | -0.9 | ||||
Operating Margin | (4.91) % | ||||
Current Valuation | 21.91 M | ||||
Shares Outstanding | 21.04 M | ||||
Shares Owned By Insiders | 10.17 % | ||||
Shares Owned By Institutions | 73.51 % | ||||
Number Of Shares Shorted | 826.91 K | ||||
Price To Earning | (2.04) X | ||||
Price To Book | 14.50 X | ||||
Price To Sales | 0.69 X | ||||
Revenue | 7.19 M | ||||
Gross Profit | (24.77 M) | ||||
EBITDA | (43.88 M) | ||||
Net Income | (50.08 M) | ||||
Cash And Equivalents | 13.21 M | ||||
Cash Per Share | 1.87 X | ||||
Total Debt | 49.5 M | ||||
Debt To Equity | 6.64 % | ||||
Current Ratio | 1.87 X | ||||
Book Value Per Share | (6.91) X | ||||
Cash Flow From Operations | (48.14 M) | ||||
Short Ratio | 1.26 X | ||||
Earnings Per Share | (0.03) X | ||||
Target Price | 5.0 | ||||
Number Of Employees | 113 | ||||
Beta | 0.38 | ||||
Market Capitalization | 10.48 M | ||||
Total Asset | 34.8 M | ||||
Retained Earnings | (584.3 M) | ||||
Working Capital | (30.96 M) | ||||
Current Asset | 77.78 M | ||||
Current Liabilities | 18.54 M | ||||
Net Asset | 34.8 M |
About T2 Biosystms Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze T2 Biosystms's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of T2 Biosystms using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of T2 Biosystms based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts. T2 Biosystems operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 182 people.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Other Consideration for investing in TTOO Pink Sheet
If you are still planning to invest in T2 Biosystms check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the T2 Biosystms' history and understand the potential risks before investing.
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
CEOs Directory Screen CEOs from public companies around the world | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |